Literature DB >> 11587764

The 'biodrug' concept: an innovative approach to therapy.

S Blanquet1, S Marol-Bonnin, E Beyssac, D Pompon, M Renaud, M Alric.   

Abstract

Cell engineering technology using recombinant microorganisms has created new opportunities in the development of innovative drugs. This article presents the use of living genetically engineered microorganisms, such as bacteria or yeasts, as a new delivery vehicle to the gastrointestinal tract. This 'biodrug' concept was demonstrated using recombinant Saccharomyces cerevisiae expressing the plant cytochrome P450 73A1. This enzyme provides a relevant model for potential therapeutic applications, such as 'biodetoxication' in the digestive environment. An artificial gastrointestinal tract simulating human digestion was chosen as a powerful tool to validate the biodrug concept. This approach offers a novel strategy for drug discovery and testing.

Entities:  

Mesh:

Year:  2001        PMID: 11587764     DOI: 10.1016/S0167-7799(01)01739-5

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  11 in total

1.  Digestion of starch in a dynamic small intestinal model.

Authors:  M R Jaime-Fonseca; O Gouseti; P J Fryer; M S J Wickham; S Bakalis
Journal:  Eur J Nutr       Date:  2015-12-19       Impact factor: 5.614

2.  Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.

Authors:  Laura Edwards-Ingram; Paul Gitsham; Nicola Burton; Geoff Warhurst; Ian Clarke; David Hoyle; Stephen G Oliver; Lubomira Stateva
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

3.  Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.

Authors:  S Blanquet; J P Meunier; M Minekus; S Marol-Bonnin; M Alric
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

4.  A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions.

Authors:  Stéphanie Blanquet; Evelijn Zeijdner; Erick Beyssac; Jean-Philippe Meunier; Sylvain Denis; Robert Havenaar; Monique Alric
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 5.  Application of anhydrobiosis and dehydration of yeasts for non-conventional biotechnological goals.

Authors:  Alexander Rapoport; Benedetta Turchetti; Pietro Buzzini
Journal:  World J Microbiol Biotechnol       Date:  2016-04-27       Impact factor: 3.312

6.  Recombinant Saccharomyces cerevisiae strain expressing a model cytochrome P450 in the rat digestive environment: viability and bioconversion activity.

Authors:  G Garrait; J F Jarrige; S Blanquet; E Beyssac; M Alric
Journal:  Appl Environ Microbiol       Date:  2007-04-06       Impact factor: 4.792

7.  Cell engineering and molecular pharming for biopharmaceuticals.

Authors:  M A Abdullah; Anisa Ur Rahmah; A J Sinskey; C K Rha
Journal:  Open Med Chem J       Date:  2008-05-14

Review 8.  Yeast Cells in Microencapsulation. General Features and Controlling Factors of the Encapsulation Process.

Authors:  Giulia Coradello; Nicola Tirelli
Journal:  Molecules       Date:  2021-05-24       Impact factor: 4.411

9.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640

10.  In vivo targeted delivery of CD40 shRNA to mouse intestinal dendritic cells by oral administration of recombinant Sacchromyces cerevisiae.

Authors:  L Zhang; T Zhang; L Wang; S Shao; Z Chen; Z Zhang
Journal:  Gene Ther       Date:  2014-05-29       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.